Episode Details
Back to Episodes
Jun 29, 2026 | Orforglipron PDUFA Tomorrow: Lilly Trades Above Consensus
Published 3 weeks, 3 days ago
Description
Lilly at $1,230 — trading above analyst consensus — as orforglipron faces its FDA verdict tomorrow. Three label items to watch beyond the headline, plus healthcare's dramatic sub-sector bifurcation: drug makers up 25% YTD while devices crater.
Www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, orforglipron, Eli Lilly, LLY, GLP-1, oral GLP-1, PDUFA, obesity, type 2 diabetes, healthcare sector, XBI, JNJ, Johnson & Johnson, UnitedHealth, UNH, Abbott, Merck, Gilead, medical devices, Intuitive Surgical, Thermo Fisher, Lilly, Amgen